lestaurtinib has been researched along with pd 184352 in 2 studies
| Studies (lestaurtinib) | Trials (lestaurtinib) | Recent Studies (post-2010) (lestaurtinib) | Studies (pd 184352) | Trials (pd 184352) | Recent Studies (post-2010) (pd 184352) |
|---|---|---|---|---|---|
| 124 | 12 | 63 | 185 | 3 | 74 |
| Protein | Taxonomy | lestaurtinib (IC50) | pd 184352 (IC50) |
|---|---|---|---|
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.012 | |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 0.0263 | |
| Casein kinase II subunit alpha | Homo sapiens (human) | 0.017 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 0.0218 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
2 other study(ies) available for lestaurtinib and pd 184352
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |